The U.S. Food and Drug Administration announced on April 30 2026 that it is proposing to remove the active ingredients of Eli Lilly’s tirzepatide—used in the obesity and diabetes drugs Zepbound and Mounjaro—from the 503B bulk compounding list. The proposal also extends to semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, which are not Lilly products. The FDA’s rationale is that, because FDA‑approved versions of these drugs are available, there is no “clinical need” for outsourcing facilities to compound them from bulk substances.
The proposal would prevent 503B outsourcing facilities from legally compounding tirzepatide and semaglutide unless a clear clinical need exists. By limiting the ability to produce cheaper, custom‑made versions, the FDA aims to protect the pricing and supply chain advantages that Lilly and Novo Nordisk have built for their GLP‑1 drugs. The move is a regulatory win for both companies, which have faced growing competition from generic and biosimilar alternatives.
The public comment period for the proposal runs until June 29 2026, giving stakeholders time to submit feedback on the agency’s reasoning and the potential impact on patient access and market dynamics. The FDA’s action reflects a broader effort to curb the compounding of GLP‑1 drugs, which had flourished during shortages and the availability of lower‑cost alternatives.
Lilly’s Q1 2026 earnings, released on the same day, showed revenue of $19.8 billion—an increase of 56% year‑over‑year—and diluted EPS of $8.26, beating analyst expectations by $0.24. The earnings beat was driven by strong volume growth in Mounjaro and Zepbound, which together generated $12.8 billion in revenue. Management attributed the performance to sustained demand for GLP‑1 therapy and the recent launch of the oral obesity pill Foundayo, which expands the patient population that can use GLP‑1 drugs.
The company raised its full‑year 2026 revenue guidance to $82.0 billion–$85.0 billion and non‑GAAP EPS guidance to $35.50–$37.00, up from the prior guidance of $81.9 billion and $34.39. The guidance increase signals confidence in continued demand for Lilly’s core products and the pipeline, despite headwinds such as lower realized prices for Mounjaro and Zepbound. Gross margin as a percentage of revenue slightly decreased to 81.9% from 82.6% in Q1 2025, primarily due to lower realized prices, while the non‑GAAP performance margin improved to 50% from 43% in the prior year.
The FDA proposal, combined with Lilly’s strong earnings and upward guidance, is expected to reinforce the company’s market position and pricing power. By limiting the availability of cheaper, compounded versions of its drugs, Lilly can maintain higher margins and protect its supply chain, while the regulatory action also signals to competitors that the FDA will enforce strict controls on GLP‑1 compounding. The combined effect of the regulatory win and robust financial performance positions Lilly for continued growth in the obesity and diabetes markets.
The market reaction to the proposal and earnings was positive, with analysts noting the significance of the regulatory win and the company’s ability to sustain high growth rates. Investors viewed the guidance raise as a sign of confidence in the company’s pipeline and market demand, while the FDA’s stance on compounding was seen as a protective measure for the industry’s pricing structure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.